Evgen Pharma PLC CEO Dr Huw Jones speaks to Proactive following the signing of a partnership deal with Stalicla SA to investigate the use of Evgen’s lead SFX-01 as a potential treatment for autism spectrum disorder and other central nervous system disorders.
The deal will be worth up to US$160.5mln if all milestones are passed.
Stalicla, which specialises in identifying specific phenotypes of autism spectrum disorder (ASD), will pay US$0.5mln upfront.
#proactiveinvestors #EvgenPharma
